Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCTXNASDAQ:DRUGNASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTXBriacell Therap$2.98+0.7%$3.55$2.78▼$29.40$20.20M1.31570,852 shs57,892 shsDRUGBright Minds Biosciences$26.39+13.4%$29.56$0.93▼$79.02$185.79M-5.7450,751 shs42,364 shsRXRXRecursion Pharmaceuticals$5.08+1.0%$4.88$3.79▼$12.36$2.06B0.8415.72 million shs22.49 million shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTXBriacell Therap0.00%-3.27%-13.45%-18.90%-82.69%DRUGBright Minds Biosciences0.00%-14.79%-10.50%-35.49%+2,045.49%RXRXRecursion Pharmaceuticals0.00%0.00%+19.76%-4.91%-32.93%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCTXBriacell Therap3.0363 of 5 stars3.55.00.00.03.10.00.6DRUGBright Minds Biosciences3.1976 of 5 stars3.63.00.00.04.02.50.0RXRXRecursion Pharmaceuticals2.0422 of 5 stars3.21.00.00.03.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCTXBriacell Therap 3.00Buy$32.00973.83% UpsideDRUGBright Minds Biosciences 3.25Buy$83.25215.46% UpsideRXRXRecursion Pharmaceuticals 2.33Hold$7.0037.80% UpsideCurrent Analyst Ratings BreakdownLatest BCTX, DRUG, and RXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025RXRXRecursion PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $5.005/21/2025DRUGBright Minds BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/13/2025DRUGBright Minds BiosciencesCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/13/2025DRUGBright Minds BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025DRUGBright Minds BiosciencesTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/7/2025DRUGBright Minds BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.005/6/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $8.004/22/2025BCTXBriacell TherapHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/10/2025RXRXRecursion PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$10.00 ➝ $8.004/8/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCTXBriacell TherapN/AN/AN/AN/A($2.20) per shareN/ADRUGBright Minds BiosciencesN/AN/AN/AN/A$0.92 per shareN/ARXRXRecursion Pharmaceuticals$58.84M35.09N/AN/A$2.61 per share1.95Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCTXBriacell Therap-$4.79M-$8.32N/AN/AN/AN/A-479.97%-182.26%N/ADRUGBright Minds Biosciences-$2.06M-$0.36N/AN/AN/AN/A-14.56%-14.29%8/13/2025 (Estimated)RXRXRecursion Pharmaceuticals-$463.66M-$1.77N/AN/AN/A-961.32%-74.70%-54.02%8/6/2025 (Estimated)Latest BCTX, DRUG, and RXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/13/2025Q3 2025BCTXBriacell Therap-$1.76-$1.64+$0.12-$1.64N/AN/A5/15/2025Q2 2025DRUGBright Minds Biosciences-$0.39-$0.29+$0.10-$0.29N/AN/A5/5/2025Q1 2025RXRXRecursion Pharmaceuticals-$0.44-$0.50-$0.06-$0.50$18.12 million$14.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCTXBriacell TherapN/AN/AN/AN/AN/ADRUGBright Minds BiosciencesN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCTXBriacell TherapN/A3.413.41DRUGBright Minds BiosciencesN/A126.01126.01RXRXRecursion Pharmaceuticals0.024.114.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCTXBriacell Therap15.42%DRUGBright Minds Biosciences40.52%RXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipBCTXBriacell Therap5.73%DRUGBright Minds Biosciences42.66%RXRXRecursion Pharmaceuticals8.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCTXBriacell Therap86.78 million6.39 millionOptionableDRUGBright Minds BiosciencesN/A7.04 million4.04 millionNot OptionableRXRXRecursion Pharmaceuticals400406.49 million372.23 millionOptionableBCTX, DRUG, and RXRX HeadlinesRecent News About These CompaniesRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 4.5% - Should You Buy?3 hours ago | marketbeat.comMIT & Recursion Unveil Boltz-2, Accelerates Drug Discovery 1000x, Rivals Physics-Based AccuracyJune 30 at 3:11 AM | msn.comRecursion Pharmaceuticals Inc Class A RXRX - MorningstarJune 28 at 1:37 PM | morningstar.comMWhy This Wildcard Stock Could Be a Future StarJune 28 at 1:37 PM | msn.comRecursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to NoteJune 27 at 6:51 PM | zacks.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 1.2% - Time to Sell?June 26, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down - Here's What HappenedJune 26, 2025 | marketbeat.comMorgan Stanley Trims Recursion (RXRX) Price Target, Maintains Equal Weight RatingJune 26, 2025 | msn.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 3.9% - What's Next?June 25, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 7.3% - Time to Buy?June 24, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Rating of "Hold" from AnalystsJune 24, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 1.1% - What's Next?June 23, 2025 | marketbeat.comRecursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for InvestorsJune 20, 2025 | zacks.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Position Boosted by SG Americas Securities LLCJune 20, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 5.6% - Here's What HappenedJune 19, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 6.5% - Time to Buy?June 18, 2025 | marketbeat.comExpert Outlook: Recursion Pharmaceuticals Through The Eyes Of 4 AnalystsJune 17, 2025 | benzinga.comMorgan Stanley Lowers Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target to $5.00June 16, 2025 | marketbeat.comIs This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy?June 16, 2025 | fool.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 2.2% - Here's WhyJune 13, 2025 | marketbeat.comLeerink Partnrs Has Positive Estimate for RXRX Q2 EarningsJune 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeWith Novo Nordisk's CEO Out, Wall Street Wants an American LeaderBy Leo Miller | June 7, 2025View With Novo Nordisk's CEO Out, Wall Street Wants an American LeaderAnalysts Can't Get Enough of These Little-Known Biopharma StocksBy Nathan Reiff | June 12, 2025View Analysts Can't Get Enough of These Little-Known Biopharma StocksNektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?By Leo Miller | June 28, 2025View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIABy Leo Miller | June 12, 2025View IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIABCTX, DRUG, and RXRX Company DescriptionsBriacell Therap NASDAQ:BCTX$2.98 +0.02 (+0.68%) As of 03:35 PM EasternBriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Bright Minds Biosciences NASDAQ:DRUG$26.39 +3.12 (+13.41%) As of 03:38 PM EasternBright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Recursion Pharmaceuticals NASDAQ:RXRX$5.08 +0.05 (+0.99%) As of 03:40 PM EasternRecursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
